Matricelf is a biotechnology company in the field of tissue engineering located in Tel Aviv, Israel. The company develops a platform for autologous (personal) 3D printing of tissues and organs that significantly reduce the risk of implant rejection. Matricelf developed a technology that enables the production of autologous engineered tissue composed of matrix and cells derived from patients Omentum biopsy. The platform showed remarkable pre-clinical results for several medical conditions. The company recently licensed the technology that enabled scientist at Tel Aviv university to 3D print a human heart from human cells and matrix for the first time in human history. For its first clinical application, Matricelf focuses on spinal cord implants for patients suffering from traumatic Spinal Cord Injuries and plans to conduct its first human clinical trial for Acute Spinal Cord Injury (SCI) in 2023.